EA202090716A1 - THE APPLICATION OF MODIFIED T-CELLS WITH CHIMERIC ANTIGENIC RECEPTORS FOR THE TREATMENT OF MALIGNANT NOMINATIONS - Google Patents

THE APPLICATION OF MODIFIED T-CELLS WITH CHIMERIC ANTIGENIC RECEPTORS FOR THE TREATMENT OF MALIGNANT NOMINATIONS

Info

Publication number
EA202090716A1
EA202090716A1 EA202090716A EA202090716A EA202090716A1 EA 202090716 A1 EA202090716 A1 EA 202090716A1 EA 202090716 A EA202090716 A EA 202090716A EA 202090716 A EA202090716 A EA 202090716A EA 202090716 A1 EA202090716 A1 EA 202090716A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nominations
malignant
modified
cells
treatment
Prior art date
Application number
EA202090716A
Other languages
Russian (ru)
Inventor
Карл Х. Джун
Дэвид Л. Портер
Майкл Д. Кейлос
Майкл С. Майлон
Original Assignee
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания filed Critical Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Publication of EA202090716A1 publication Critical patent/EA202090716A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение относится к композициям и способам лечения злокачественных новообразований у человека. Изобретение относится к введению генетически модифицированной Т-клетки для экспрессии CAR, где CAR содержит антигенсвязывающий домен, трансмембранный домен, костимуляторную сигнальную область и сигнальный домен CD3-дзета.The present invention relates to compositions and methods for treating malignant neoplasms in humans. The invention relates to the introduction of a genetically modified T cell for expression of CAR, where the CAR contains an antigen-binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3-zeta signaling domain.

EA202090716A 2011-06-29 2011-12-09 THE APPLICATION OF MODIFIED T-CELLS WITH CHIMERIC ANTIGENIC RECEPTORS FOR THE TREATMENT OF MALIGNANT NOMINATIONS EA202090716A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161502649P 2011-06-29 2011-06-29

Publications (1)

Publication Number Publication Date
EA202090716A1 true EA202090716A1 (en) 2021-03-31

Family

ID=52395350

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090716A EA202090716A1 (en) 2011-06-29 2011-12-09 THE APPLICATION OF MODIFIED T-CELLS WITH CHIMERIC ANTIGENIC RECEPTORS FOR THE TREATMENT OF MALIGNANT NOMINATIONS

Country Status (3)

Country Link
CU (1) CU20130079A7 (en)
EA (1) EA202090716A1 (en)
TN (1) TN2013000246A1 (en)

Also Published As

Publication number Publication date
CU20130079A7 (en) 2013-09-27
TN2013000246A1 (en) 2014-11-10

Similar Documents

Publication Publication Date Title
CY1120707T1 (en) ANTI-CD28 HUMANIZED ANTIBODIES
LTPA2019503I1 (en) Use of Modified T Cells Containing Chimeric Antigen Receptors for Cancer Treatment
CY1123145T1 (en) ANTI-CD40 ANTIBODIES
EA201491573A1 (en) APPLICATION OF TRANSMITTING SIGNAL OF DOMAIN CD2 IN CHEMERIC ANTIGENSPECIFIC RECEPTORS OF THE SECOND GENERATION
EA201491574A1 (en) APPLICATION OF CAR, BASED ON ICOS, TO STRENGTHEN ANTI-TUMOR ACTIVITY AND LONG-TERM CAR SAVING
EA201592269A1 (en) METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS
IN2014MN01879A (en)
EA201491811A1 (en) ANTI-LgR5 ANTIBODIES AND IMMUNOCONJUGATES
PH12014501758B1 (en) Cd47 antibodies and methods of use thereof
UY35468A (en) CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
EA201590209A1 (en) APPLICATION OF CART19 TO DEPLETE NORMAL B-CELLS FOR TOLERANCE INDUCTION
EA201490636A1 (en) T-CELLS DESIGNED WITH THE HELP OF RNA FOR THE TREATMENT OF MALIGNOUS NON-FORMATIONS
EA201590993A1 (en) HETERODIMERNY IMMUNOHLOBULINS
EA201590173A1 (en) IMMUNOCONGUTS CONTAINING ANTIBODIES TO CD22
EA201990575A2 (en) CD19-SPECIFIC CHIMERIC ANTIGENIC RECEPTOR AND ITS APPLICATIONS
AR090973A1 (en) USEFUL ANTIBODIES FOR CANCER DIAGNOSIS
EA201390933A1 (en) ANTIBODIES AGAINST MEZOTELINE AND IMMUNOCONJUGATES
EA201490778A1 (en) ANTIBODIES AGAINST HtrA1 AND METHODS OF APPLICATION
EA201590172A1 (en) IMMUNOCONGATES CONTAINING ANTIBODIES TO CD79b
EA201391540A1 (en) FGFR1 AGONISTS AND METHODS OF THEIR APPLICATION
EA201200999A1 (en) METHODS OF TREATMENT BREAST CANCER
GT201200096A (en) MONOCLONAL ANTIBODIES
EA201490850A1 (en) COMPOSITION OF ANTIBODY SUITABLE FOR THE PREVENTION AND TREATMENT OF AMYLOIDOSIS, ITS OPTIONS AND METHOD FOR ITS OBTAINING
EA201892509A1 (en) ANTIBODIES TO HEMAGGLUTININ AND METHODS OF APPLICATION
UA113879C2 (en) HUMANIZED TRK ANTITILE ANTIBODY